Neurological disorders

Infarmed's first Deep Dive looks at migraine medicines in Portugal. In 2025, more than 73,000 people used SNS-reimbursed migraine therapies, 85% of them women. Patients paid about €6 million (61%) of the €9.9 million pharmacy bill, and atogepant, funded only at the end of 2024, already led spending. #SyenzaNews #Migraine #MarketAccess #Portugal

The FDA has launched the Neuroscience Advancement and Innovation Nexus, starting with an Alzheimer's Prevention Accelerator. #SyenzaNews #Alzheimers #MarketAccess

Researchers and Allegheny County plan a $13.3 million trial of weekly semaglutide to reduce opioid and alcohol use and justice involvement.

A University of Minnesota model fine-tuned on routine clinical notes separated epileptic from psychogenic seizures with an AUC of up to 0.875, and helped neurologists lift their own accuracy by up to 14.3 percentage points. #SyenzaNews #epilepsy #AI #digitalhealth #MarketAccess

EMEA and GBEI brought China, Malaysia, Japan and India together to map an Asian brain economy strategy, framing brain capital as core economic infrastructure and introducing the Asian Brain Economy Index. #BrainEconomy #BrainCapital #Asia #BrainHealth

Smartphone AI is transforming teen mental health detection. A new npj Digital Medicine study shows speech-based AI identified depression with AUROC 0.95 in 1,838 Chinese adolescents. Read the groundbreaking research today! #AI #MentalHealth #DigitalHealth #TeenDepression

What's powering Novartis's Q2 sales rebound? The pharma leader has posted renewed growth, fueled by strong momentum from its latest product launches across key portfolios. These results highlight the company's strategic focus on innovation and pipeline delivery. Read the full breakdown on Syenza. #SyenzaNews #pharmaceuticals #biotech #innovation #MarketAccess

Could a Phase III win make botulinum toxin a dual‑indication migraine therapy? 🔬📈 A recent Phase III program showed positive efficacy and safety for botulinum toxin in episodic migraine, supporting regulatory filings that could expand its label beyond chronic migraine—opening new treatment options for patients and commercial opportunities for sponsors. Read the full article to learn trial highlights, regulatory implications, and what this means for clinicians and market access teams. #SyenzaNews #clinicaltrials #drugdevelopment #MarketAccess #innovation

How can better preparation of calcified carotid lesions change stroke outcomes? 🧠 Calcified plaques complicate carotid interventions, but targeted lesion preparation — from intravascular lithotripsy and atherectomy to advanced imaging and embolic protection — can improve stent expansion and reduce periprocedural stroke risk. The article outlines device options, imaging-guided planning, and practical strategies for multidisciplinary teams. Read the full piece to see which approaches are showing the best balance of safety and efficacy. #SyenzaNews #medicaldevices #medicalimaging #innovation #healthcarepolicy

Could data-driven care pathways transform treatment for major depressive disorder? 🧠 This article outlines how treatment-pathway modeling uses patient data and simulation to identify optimal sequencing, improve remission rates, and guide resource allocation—balancing clinical outcomes with economic impact. It highlights practical implications for clinicians, payers, and policymakers seeking more personalized, cost-effective MDD care. Read the full analysis to explore the models, key findings, and next steps for implementation. #SyenzaNews #AIinHealthcare #HealthTech #innovation #costeffectiveness

🔬 Levacetylleucine Phase 3 results are out — what do they mean for patients and the future of treatment? This article breaks down the trial’s key findings, safety signals, and regulatory implications for levacetylleucine, highlighting what clinicians, payers, and investors should watch next. Read the full analysis to understand the endpoints, next steps toward approval, and the potential industry impact. #SyenzaNews #clinicaltrials #drugdevelopment #innovation #healthcarepolicy

Can more precise cognitive measurement change how we forecast Parkinson’s progression? The article explores how sensitive cognitive tests, digital assessments and biomarker-informed models — powered by machine learning — can improve accuracy in predicting cognitive decline in Parkinson’s disease, with clear benefits for trial design and personalized care 🧠📈. Read the full piece to see the key methods, validation findings, and practical steps for adopting these tools in research and clinical settings. #SyenzaNews #digitalhealth #AIinHealthcare #ai #datascience